

**Amendments to the Claims:**

This listing of claims will replace all prior version, and listings, of claims in the application:

**Listing of Claims:**

1. (CURRENTLY AMENDED) A method, comprising:
  - (a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and (ii) a formulation comprising an inhibitor that specifically inhibits Type 4 cyclic adenosine ~~monophosphate~~ monophosphate phosphodiesterases; and
  - (b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.
2. (ORIGINAL) The method of Claim 1, wherein said administering is enteral administration.
3. (ORIGINAL) The method of Claim 2, wherein said enteral administration is oral administration.
4. (ORIGINAL) The method of Claim 1, wherein said administering is parenteral administration.
5. (ORIGINAL) The method of Claim 1, wherein said patient is a naïve patient.
6. (ORIGINAL) The method of Claim 1, wherein said patient is immunocompromised.
7. (ORIGINAL) The method of Claim 1, wherein said patient is unresponsive to chemotherapy with alkylating agents.
8. (CANCELLED)
9. (CANCELLED)

10. (CANCELLED)
11. (CANCELLED)
12. (CANCELLED)
13. (CANCELLED)
14. (CANCELLED)
15. (CURRENTLY AMENDED) ~~The method of claim 1, wherein the inhibitor is A method, comprising:~~
  - (a) providing: i) a patient having symptoms of chronic lymphocytic leukemia, and ii) a formulation comprising an inhibitor that specifically inhibits Type 4 cyclic adenosine monophosphate phosphodiesterases, wherein said inhibitor is (4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone) referred to as XX5; and
  - (b) administering a therapeutically effective dose of said formulation to said patient under conditions such that said symptoms are reduced.